CL2013002823A1 - Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer. - Google Patents

Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.

Info

Publication number: CL2013002823A1
Authority: CL; Chile
Prior art keywords: morpholinothieno; hydroxypyrimidine; pyrimidin; carboxamide; methylamino
Prior art date: 2011-04-01

Application number

CL2013002823A

Other languages

English (en)

Spanish (es)

Inventor

Xiong Cai

Haixiao Zhai

Chengjung Lai

Changgeng Qian

Rudi Bao

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2013-09-30

Publication date

2014-04-11

2013-09-30 Application filed by Curis Inc filed Critical Curis Inc

2014-04-11 Publication of CL2013002823A1 publication Critical patent/CL2013002823A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000035269 cancer or benign tumor Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
-1 morpholinothieno [3,2-d] pyrimidin-6-yl-methyl- (methylamino) Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2013002823A 2011-04-01 2013-09-30 Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer. CL2013002823A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161470849P	2011-04-01	2011-04-01
US201161559489P	2011-11-14	2011-11-14

Publications (1)

Publication Number	Publication Date
CL2013002823A1 true CL2013002823A1 (es)	2014-04-11

Family

ID=46931927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002823A CL2013002823A1 (es)	2011-04-01	2013-09-30	Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.

Country Status (29)

Country	Link
US (7)	US8710219B2 (2)
EP (2)	EP2694075B1 (2)
JP (3)	JP6242331B2 (2)
KR (2)	KR101902325B1 (2)
CN (2)	CN103582483B (2)
AU (1)	AU2012236367B2 (2)
BR (1)	BR112013025340B1 (2)
CA (1)	CA2830822C (2)
CL (1)	CL2013002823A1 (2)
CY (2)	CY1117785T1 (2)
DK (2)	DK3111938T3 (2)
EA (1)	EA022434B9 (2)
ES (2)	ES2577982T3 (2)
HR (2)	HRP20160545T1 (2)
HU (2)	HUE045041T2 (2)
IL (2)	IL228588A (2)
LT (1)	LT3111938T (2)
ME (2)	ME02451B (2)
MX (1)	MX340577B (2)
PE (1)	PE20141382A1 (2)
PL (2)	PL2694075T3 (2)
PT (2)	PT3111938T (2)
RS (2)	RS59219B1 (2)
SG (2)	SG10201602569RA (2)
SI (2)	SI2694075T1 (2)
SM (2)	SMT201900435T1 (2)
TW (1)	TWI571469B (2)
WO (1)	WO2012135571A1 (2)
ZA (2)	ZA201307082B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9522902B2 (en)	2011-11-14	2016-12-20	Ignyta, Inc.	Uracil derivatives as AXL and c-MET kinase inhibitors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010203512C1 (en)	2009-01-08	2013-10-17	Curis, Inc.	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
DK3111938T3 (da)	2011-04-01	2019-07-01	Curis Inc	Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
CN104725301A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种1,2-二氢吡啶-2-酮衍生物的制备方法
US10227347B2 (en)	2015-04-21	2019-03-12	Guizhou Bailing Group Pharmaceutical Co., Ltd.	Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
US11142552B2 (en) *	2016-07-19	2021-10-12	National Institute Of Plant Genome Research	Protein against fungal pathogens
WO2018085342A1 (en) *	2016-11-02	2018-05-11	Curis, Inc.	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN111801102B (zh) *	2017-11-06	2024-05-28	冷泉港实验室	用于形成含铜络合物的方法和组合物及其用途
SG11202102343QA (en)	2018-09-11	2021-04-29	Curis Inc	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EP3968215A1 (en)	2020-09-09	2022-03-16	Koninklijke Philips N.V.	Determining target object type and position
WO2023212574A1 (en) *	2022-04-26	2023-11-02	Olivia Szu Hsieh Lee Nakaya	Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en)	1984-01-31	1989-05-09	Akzo N.V.	Tumor specific monoclonal antibodies
US5369108A (en)	1991-10-04	1994-11-29	Sloan-Kettering Institute For Cancer Research	Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en)	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en)	1993-05-21	1996-03-12	Aradigm Corporation	Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en)	1994-10-19	1996-04-16	Pathogenesis Corporation	Aminoglycoside formulation for aerosolization
US6777217B1 (en)	1996-03-26	2004-08-17	President And Fellows Of Harvard College	Histone deacetylases, and uses related thereto
US6083922A (en)	1996-04-02	2000-07-04	Pathogenesis, Corp.	Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en)	1997-02-13	1998-06-16	Pathogenesis Corporation	Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CN1186324C (zh)	2000-04-27	2005-01-26	山之内制药株式会社	稠合杂芳基衍生物
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
OA12793A (en)	2002-03-13	2006-07-10	Janssen Pharmaceutica Nv	Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
ES2306859T3 (es)	2002-03-13	2008-11-16	Janssen Pharmaceutica Nv	Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
MXPA04008796A (es)	2002-03-13	2004-11-26	Janssen Pharmaceutica Nv	Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
DE60326436D1 (en)	2002-03-13	2009-04-16	Janssen Pharmaceutica Nv	Aminoderivate als histone-deacetylase-inhibitoren
WO2004017950A2 (en)	2002-08-22	2004-03-04	Piramed Limited	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7300935B2 (en)	2003-01-29	2007-11-27	Takeda Pharmaceutical Company	Thienopyrimidine compounds and use thereof
WO2005097747A1 (en)	2004-04-05	2005-10-20	Aton Pharma, Inc.	Histone deacetylase inhibitor prodrugs
WO2005117909A2 (en)	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
EP1806347A4 (en)	2004-10-08	2009-07-01	Astellas Pharma Inc	PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
NZ589276A (en)	2005-02-03	2012-06-29	Topotarget Uk Ltd	Combination therapies using hdac inhibitors and erlotinib (tarceva)
AU2006248938B2 (en)	2005-05-18	2011-09-29	Janssen Pharmaceutica N.V.	Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2007206942B2 (en)	2006-01-19	2012-08-23	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7834011B2 (en)	2006-01-19	2010-11-16	Janssen Pharmaceutica N.V.	Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
WO2007082880A1 (en)	2006-01-19	2007-07-26	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
MX2008013578A (es)	2006-04-26	2009-03-23	Hoffmann La Roche	Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101511840A (zh)	2006-04-26	2009-08-19	吉宁特有限公司	磷酸肌醇3-激酶抑制剂化合物及其使用方法
TWI498332B (zh)	2006-04-26	2015-09-01	Hoffmann La Roche	作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
WO2007131364A1 (en)	2006-05-16	2007-11-22	Mcgill University	Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
EP2061772A4 (en)	2006-09-11	2011-06-29	Curis Inc	MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
CA2663147A1 (en)	2006-09-11	2008-03-20	Curis, Inc.	Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
CN101535279B (zh)	2006-09-11	2015-05-20	柯瑞斯公司	含锌结合基的喹唑啉基egfr抑制剂
US20080161320A1 (en)	2006-09-11	2008-07-03	Xiong Cai	Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
AU2007296743B2 (en)	2006-09-11	2012-02-16	Curis, Inc.	Tyrosine kinase inhibitors containing a zinc binding moiety
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101573333B (zh)	2006-10-28	2013-06-12	梅特希尔基因公司	组蛋白脱乙酰酶抑制剂
ES2571028T3 (es) *	2006-12-07	2016-05-23	Genentech Inc	Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
WO2008070740A1 (en)	2006-12-07	2008-06-12	F.Hoffmann-La Roche Ag	Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0807812A2 (pt)	2007-02-15	2020-06-23	Novartis Ag	Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
EP2136809A4 (en)	2007-03-20	2012-01-04	Curis Inc	INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
TW200922564A (en)	2007-09-10	2009-06-01	Curis Inc	CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Mek inhibitors containing a zinc binding moiety
WO2009036066A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Vegfr inhibitors containing a zinc binding moiety
TW200922590A (en)	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety
WO2009036057A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Antiproliferative agents containing a zinc binding moiety
AU2008298948B2 (en)	2007-09-12	2014-09-04	F. Hoffmann-La Roche Ag	Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en)	2007-09-24	2009-04-02	Curis, Inc.	Anti-proliferative agents
US8354528B2 (en)	2007-10-25	2013-01-15	Genentech, Inc.	Process for making thienopyrimidine compounds
US20090149511A1 (en)	2007-10-30	2009-06-11	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en)	2007-12-20	2009-07-09	Curis, Inc.	Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en)	2008-06-24	2010-01-21	Takeda Pharmaceutical Company Limited	Pi3k/m tor inhibitors
WO2009155659A1 (en)	2008-06-27	2009-12-30	The University Of Queensland	Combination therapy
US8196911B2 (en)	2008-10-27	2012-06-12	Honda Motor Co., Ltd.	Adjustable rate subframe mount
AU2010203512C1 (en) *	2009-01-08	2013-10-17	Curis, Inc.	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2010089411A2 (en)	2009-02-09	2010-08-12	Universite De La Mediterranee	Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN102369011A (zh)	2009-03-12	2012-03-07	健泰科生物技术公司	用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
KR101489045B1 (ko)	2009-10-12	2015-02-02	에프. 호프만-라 로슈 아게	Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
AU2011239537A1 (en) *	2010-04-16	2012-11-15	Curis, Inc.	Treatment of cancers having K-ras mutations
DK3111938T3 (da) *	2011-04-01	2019-07-01	Curis Inc	Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130102595A1 (en)	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations
JP6238459B2 (ja)	2011-08-01	2017-11-29	ジェネンテック，インコーポレイテッド	Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
EP4257134A3 (en)	2015-06-25	2024-01-24	Immunomedics, Inc.	Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2018085342A1 (en) *	2016-11-02	2018-05-11	Curis, Inc.	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

2012
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en not_active Ceased
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 SM SM20190435T patent/SMT201900435T1/it unknown
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active Active
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Ceased
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
2016
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9522902B2 (en)	2011-11-14	2016-12-20	Ignyta, Inc.	Uracil derivatives as AXL and c-MET kinase inhibitors
US9745283B2 (en)	2011-11-14	2017-08-29	Ignyta, Inc.	Uracil derivatives as AXL and c-MET kinase inhibitors
US10017496B2 (en)	2011-11-14	2018-07-10	Ignyta, Inc.	Uracil derivatives as AXL and c-MET kinase inhibitors

Also Published As

Publication number	Publication date
US20140243330A1 (en)	2014-08-28
CY1117785T1 (el)	2017-05-17
CY1121825T1 (el)	2020-07-31
US20130090335A1 (en)	2013-04-11
HK1194969A1 (zh)	2014-10-31
US20160185796A1 (en)	2016-06-30
EP2694075B1 (en)	2016-04-27
RS54903B1 (sr)	2016-10-31
EA022434B9 (ru)	2016-02-29
NZ705039A (en)	2016-03-31
EP3111938A1 (en)	2017-01-04
CN103582483A (zh)	2014-02-12
JP2018052987A (ja)	2018-04-05
ES2733128T3 (es)	2019-11-27
BR112013025340A2 (pt)	2016-12-13
EA201301114A1 (ru)	2014-04-30
KR20180108848A (ko)	2018-10-04
DK3111938T3 (da)	2019-07-01
JP6275784B2 (ja)	2018-02-07
TW201247678A (en)	2012-12-01
AU2012236367B2 (en)	2014-10-09
ME03523B (me)	2020-04-20
CN105461736A (zh)	2016-04-06
TWI571469B (zh)	2017-02-21
JP2014509653A (ja)	2014-04-21
US20190091211A1 (en)	2019-03-28
NZ615586A (en)	2015-02-27
US8710219B2 (en)	2014-04-29
HRP20191091T1 (hr)	2019-09-20
MX340577B (es)	2016-07-13
US20200215039A1 (en)	2020-07-09
PE20141382A1 (es)	2014-11-04
IL228588A (en)	2016-11-30
KR20140023333A (ko)	2014-02-26
AU2012236367A1 (en)	2013-04-18
PL3111938T3 (pl)	2019-09-30
US10111864B2 (en)	2018-10-30
US11654136B2 (en)	2023-05-23
HUE028910T2 (en)	2017-01-30
HUE045041T2 (hu)	2019-12-30
US20170304279A1 (en)	2017-10-26
LT3111938T (lt)	2019-06-25
CN105461736B (zh)	2018-06-12
IL248597B (en)	2018-04-30
ZA201406167B (en)	2015-03-25
ME02451B (me)	2016-09-20
EP2694075A1 (en)	2014-02-12
US20220168284A1 (en)	2022-06-02
CA2830822C (en)	2018-10-02
US10543197B2 (en)	2020-01-28
IL248597A0 (en)	2016-12-29
IL228588A0 (en)	2013-12-31
ZA201307082B (en)	2015-04-29
SMT201900435T1 (it)	2019-09-09
PL2694075T3 (pl)	2016-09-30
ES2577982T3 (es)	2016-07-19
EA022434B1 (ru)	2015-12-30
SMT201600179B (it)	2016-08-31
WO2012135571A1 (en)	2012-10-04
RS59219B1 (sr)	2019-10-31
US11135205B2 (en)	2021-10-05
HRP20160545T1 (hr)	2016-06-17
SI2694075T1 (sl)	2016-07-29
US9657032B2 (en)	2017-05-23
JP2016188255A (ja)	2016-11-04
MX2013011132A (es)	2014-03-12
JP6242331B2 (ja)	2017-12-06
PT3111938T (pt)	2019-07-10
DK2694075T3 (en)	2016-08-01
BR112013025340B1 (pt)	2021-12-21
EP3111938B1 (en)	2019-05-08
CA2830822A1 (en)	2012-10-04
US9249156B2 (en)	2016-02-02
SI3111938T1 (sl)	2019-08-30
PT2694075T (pt)	2016-07-11
CN103582483B (zh)	2016-02-17
SG10201602569RA (en)	2016-05-30
KR101902325B1 (ko)	2018-09-28
EP2694075A4 (en)	2014-10-01
SG193563A1 (en)	2013-11-29

Publication	Publication Date	Title
CL2013002823A1 (es)	2014-04-11	Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
CL2021000008A1 (es)	2021-06-11	Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2014000543A1 (es)	2014-09-26	Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014002412A1 (es)	2015-03-06	Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2013001009A1 (es)	2013-08-30	Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2013003025A1 (es)	2014-05-30	Compuestos derivados de pirimidinas de diaminocarboxamida y diaminocarbonitrilo, como inhibidores de quinasa jnk; composicion farmaceutica; metodo de inhibicion in vitro; y su uso en el tratamiento o prevencion de trastornos fibroticos del higado, diabetes o sindrome metabolico conduciendo a trastornos fibroticos del higado.
CL2014001065A1 (es)	2014-07-25	Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
CL2013002063A1 (es)	2013-12-27	Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
CL2014001729A1 (es)	2014-09-26	Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
CL2015000711A1 (es)	2015-09-04	Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2012002189A1 (es)	2012-11-23	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2014001103A1 (es)	2014-10-03	Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2014000343A1 (es)	2014-10-17	Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
BR112014028755A2 (pt)	2018-04-24	composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano.
CL2012003745A1 (es)	2013-05-31	Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
DK2922828T3 (da)	2020-08-31	4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
CL2011000454A1 (es)	2011-09-30	Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.